The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Post-Transplant Infections Timeline

Phase-specific infection risks after solid organ and stem cell transplantation, guiding prophylaxis and surveillance.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Post-Transplant Infections Timeline?

Infectious complications after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) follow a characteristic timeline that reflects the net state of immunosuppression and exposure to nosocomial and donor-derived organisms. In SOT three classical phases are recognized: early (0–1 month) dominated by surgical, nosocomial, and donor-derived infections; intermediate (1–6 months) characterized by opportunistic infections and viral reactivation; late (>6 months) when chronic and community-acquired infections predominate.

In HSCT phases include pre-engraftment (0–30 days, neutropenic with bacterial and fungal risk), early post-engraftment (30–100 days, CMV, PJP, fungal infections during graft-versus-host disease), and late post-engraftment (>100 days, encapsulated bacteria, late viral reactivations, post-transplant lymphoproliferative disorder). Donor-derived infections (donor-derived CMV, EBV, hepatitis viruses, parasitic infections) emphasize the importance of donor screening.

Prophylaxis strategies are stratified by transplant type and timeline: cotrimoxazole for PJP and Toxoplasma, valganciclovir for CMV, fluconazole or echinocandin for invasive candidiasis, isavuconazole or voriconazole for high-risk mold infection, and rituximab or rituximab-based regimens for EBV-associated PTLD. Vaccination strategies, surveillance with PCR for CMV/EBV/BK virus, and prompt evaluation of fever drive successful management.

Symptoms

Early phase: surgical site infection, anastomotic leak, catheter-related bloodstream infection, ventilator-associated pneumonia
Donor-derived: unexpected infection in recipient (West Nile, Strongyloides, lymphocytic choriomeningitis)
Intermediate phase: CMV viremia, syndrome (fever, cytopenia, end-organ disease)
PJP: subacute dyspnea, dry cough, hypoxia
Invasive aspergillosis: pulmonary infiltrates, sinus disease, cerebral lesions
Candidiasis: bloodstream infection, deep-seated abscess
Polyomavirus: BK nephropathy in kidney recipients, hemorrhagic cystitis in HSCT
EBV-associated PTLD: lymphadenopathy, organ infiltration, B symptoms
Late phase: community-acquired pneumonia, urinary tract infection, herpes zoster
Toxoplasmosis: especially heart transplant from seropositive donor
Tuberculosis: reactivation in recipients from endemic regions
Hepatitis B/C reactivation
Cryptococcosis: late onset, CNS involvement
Listeriosis: meningitis, bacteremia
Endemic mycoses (histoplasmosis, coccidioidomycosis) reactivation

Risk Factors

Type and intensity of immunosuppression
Allograft type (lung > heart > liver > kidney generally)
HSCT type (haploidentical and unrelated > matched related)
GVHD requiring intensified immunosuppression
Lymphocyte-depleting induction therapy (ATG, alemtuzumab)
Donor and recipient CMV/EBV serostatus mismatch
Hepatitis B/C donor or recipient
Pre-existing colonization (MRSA, Pseudomonas, Aspergillus)
Travel or residence in endemic regions (TB, fungi, parasites)
Diabetes mellitus, chronic kidney disease
Older age, frailty
Repeat surgery, hospitalization
Long ICU stay
Steroid pulse for rejection
Splenectomy

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Fever in any post-transplant patient
  • Respiratory symptoms with hypoxia
  • Diarrhea with weight loss or hematochezia
  • Skin lesions, ulcers, abscesses
  • Neurological symptoms (headache, seizures, focal deficits)
  • Cytopenias on routine monitoring
  • Rising creatinine in kidney recipient (BK, CMV, rejection)
  • Vesicular rash suggesting herpes zoster
  • Lymphadenopathy concerning for PTLD
  • Travel to endemic area for fever evaluation

Treatment Methods

01
Pre-transplant donor and recipient screening (CMV, EBV, HIV, hepatitis, syphilis, TB, Strongyloides per region)
02
Immunization update before transplant (live vaccines pre-transplant only)
03
Surgical prophylaxis tailored to transplant type
04
Cotrimoxazole 480-960 mg daily for PJP and Toxoplasma prophylaxis 6-12 months minimum
05
CMV prophylaxis: valganciclovir 900 mg daily for 3-6 months in high-risk D+/R-; preemptive therapy with PCR monitoring as alternative
06
Antifungal prophylaxis: fluconazole post-allo HSCT; isavuconazole or posaconazole in high-risk mold settings (lung, GVHD)
07
Hepatitis B prophylaxis with entecavir or tenofovir if HBcAb positive recipient or donor
08
BK virus PCR surveillance in kidney recipients with reduction of immunosuppression for nephropathy
09
EBV PCR monitoring; reduction of immunosuppression and rituximab for PTLD
10
Acyclovir or valacyclovir prophylaxis against HSV/VZV
11
Tuberculosis screening and isoniazid for latent infection
12
Strongyloides screening and ivermectin pre-treatment in endemic regions
13
Travel and food safety counseling
14
Influenza and pneumococcal vaccination per transplant guidelines
15
Herpes zoster vaccination (Shingrix) per program
16
Pet exposure counseling (no reptiles, careful cat litter handling)
17
Hand hygiene education
18
Multidisciplinary infection control in transplant unit
19
Transplant infectious disease consultation for any complex febrile illness
20
Post-transplant outpatient surveillance with structured checklists

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.